M.D. Anderson Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,742 sponsors by registered trial count).
M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.
M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.
Top-decile sponsor footprint
M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,201 of 1,595 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
2,692 total, page 35 of 54
Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers
NCT01624766
Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas
NCT01560949
An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)
NCT01498445
Registry Study of Thoracic Reirradiation for Non-Small Cell Lung Cancer (NSCLC) Utilizing Proton Beam Therapy or Intensity Modulated Radiation Therapy
NCT01808677
A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity
NCT01262664
Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer
NCT01582191
Fosaprepitant in Patients Receiving Ifosfamide-based Regimen
NCT01490060
Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)
NCT01531998
Lifestyle Intervention for High Risk Cancer Survivors
NCT01508273
New Magnetic Resonance Imaging and Spectroscopy Software in the Improvement of Image Quality
NCT03980535
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
NCT01572662
Breakthrough Dyspnea Fentanyl Study in Cancer Patients
NCT01515566
Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide
NCT01200004
Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
NCT01570868
Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer
NCT01548144
Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis
NCT01409200
Temsirolimus in Combination With Metformin in Patients With Advanced Cancers
NCT01529593
Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT01504126
Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass
NCT01433302
Selective Image Guided Resection of Axillary Lymph Nodes
NCT01880645
Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation
NCT01536392
Erlotinib in Combination With Pralatrexate in Advanced Malignancies
NCT01532011
Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy
NCT01938716
Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)
NCT01542684
Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients
NCT01520519
Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
NCT01372540
Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations
NCT01531361
Rocking Motion: Physiologic Effect on the Surgical Stress Response
NCT01200316
Study of 18F-Fluoro-PEG6-IPQA
NCT01320059
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
NCT01518153
Comparison of a Novel 22-gauge Core Biopsy Needle
NCT01598194
TKI258 for Metastatic Inflammatory Breast Cancer Patients
NCT01262027
Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-Controlled Analgesia For Liver and/or Pancreas
NCT01438476
Cryoablation for Invasive Breast Carcinoma Following Neoadjuvant Therapy
NCT01388777
Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome
NCT01436227
Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy
NCT01428635
Reducing Cancer Disparities Among Latinos in Texas
NCT01504919
Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG
NCT01390402
Respiratory Syncytial Virus - RSV Protocol
NCT01502072
Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic Leukemia
NCT01444716
Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)
NCT01469247
Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood
NCT01497184
SB1518 for Patients With Myelodysplastic Syndrome (MDS)
NCT01436084
Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)
NCT01444742
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
NCT01471444
In Vivo Dosimetry During Prostate Cancer Radiotherapy
NCT01307852
Preoperative Treatment With Cetuximab and/or IMC-A12
NCT00957853
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
NCT01430572
Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L)
NCT01201694
Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors
NCT01454804
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 748 |
| Phase 2 | 971 |
| Phase 3 | 96 |
| Phase 4 | 28 |
Therapeutic Areas
What is open in the M.D. Anderson Cancer Center pipeline
549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).
Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).
Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
M.D. Anderson Cancer Center: open-pipeline peers nationwide
Peers matched on 2,692 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
M.D. Anderson Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2,692 trials (± recruiting share)
- Mayo Clinic · 2,844 trials · 19% recruiting
- National Cancer Institute (NCI) · 3,257 trials · 10% recruiting
- Massachusetts General Hospital · 2,032 trials · 17% recruiting
- National Institute of Allergy and Infectious Diseases (NIAID) · 2,006 trials · 8% recruiting
Sponsors near 20% open enrollment (± trial volume)
- The University of Texas Health Science Center at San Antonio · 20% recruiting · 378 trials
- University of Georgia · 20% recruiting · 59 trials
- University of Houston · 20% recruiting · 64 trials
- Florida International University · 20% recruiting · 89 trials
Related
What to do with this M.D. Anderson Cancer Center page
2,692 registered trials is a research-attention snapshot, not an endorsement of M.D. Anderson Cancer Center or any single study.
- 549 of M.D. Anderson Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Hematopoietic and Lymphoid Cell Neoplasm is the condition M.D. Anderson Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hematopoietic and Lymphoid Cell Neoplasm trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. M.D. Anderson Cancer Center pipeline card: 2,692 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.